

[Open Peer Review on Qeios](#)

Farletuzumab

National Cancer Institute

Source

National Cancer Institute. *Farletuzumab*. NCI Thesaurus. Code C61503.

A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.